Neuvotion Launches First FDA-Cleared Product From Its Brain-Body Interface Platform

Summary

Neuvotion, founded by Chad Bouton to commercialize the research behind his Feinstein Institutes 'double neural bypass' work, announced its first FDA-cleared product: NeuStim, a non-invasive, AI-guided electrical muscle stimulation device for stroke and spinal cord injury recovery, set to launch this fall. NeuStim is the initial offering in a planned Brain-Body Interface portfolio that will eventually combine wearable muscle stimulation, spinal neuromodulation, and minimally invasive BCI technology. The company says the AI guidance can infer a user's movement intention and adjust stimulation targets accordingly, without requiring manual electrode repositioning.